Verition Fund Management
BMRN icon

Verition Fund Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Verition Fund Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,600
Closed -$237K – 3347
2024
Q4 		$237K Sell
3,600
-21,500
-86% -$1.44M ﹤0.01% 2898
2024
Q3 		$1.76M Buy
25,100
+21,400
+578% +$1.79M 0.01% 1494
2024
Q2 		$305K Hold
3,700
– – ﹤0.01% 2336
2024
Q1 		$323K Sell
3,700
-143,000
-97% -$12.8M ﹤0.01% 2257
2023
Q4 		$14.1M Buy
146,700
+120,800
+466% +$10.7M 0.11% 158
2023
Q3 		$2.29M Hold
25,900
– – 0.03% 720
2023
Q2 		$2.25M Buy
25,900
+5,500
+27% +$518K 0.03% 634
2023
Q1 		$1.98M Sell
20,400
-20,400
-50% -$2.11M 0.03% 706
2022
Q4 		$4.22M Hold
40,800
– – 0.07% 366
2022
Q3 		$3.46M Buy
+40,800
New +$3.63M 0.04% 608
2022
Q2 		– Sell
-11,200
Closed -$863K – 2389
2022
Q1 		$863K Buy
11,200
+8,600
+331% +$720K 0.01% 1578
2021
Q4 		$230K Buy
+2,600
New +$215K ﹤0.01% 2156
2020
Q3 		– Sell
-13,500
Closed -$1.67M – 1067
2020
Q2 		$1.67M Buy
13,500
+3,200
+31% +$318K 0.05% 268
2020
Q1 		$870K Hold
10,300
– – 0.03% 251
2019
Q4 		$871K Hold
10,300
– – 0.02% 491
2019
Q3 		$694K Buy
+10,300
New +$793K 0.02% 516
2019
Q2 		– Sell
-26,700
Closed -$2.37M – 1075
2019
Q1 		$2.37M Buy
26,700
+1,700
+7% +$158K 0.09% 170
2018
Q4 		$2.13M Buy
+25,000
New +$2.38M 0.15% 120
2015
Q2 		– Sell
-25,000
Closed -$3.12M – 621
2015
Q1 		$3.12M Buy
+25,000
New +$2.65M 0.36% 18

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Verition Fund Management's BMRN Position: Q2 2026 in Review

Verition Fund Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 22,500 shares worth $1.29M. The stake represents 0.01% of the portfolio and ranks #1330 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in BMRN as recently as Q4 2025.

Verition Fund Management first reported a position in BMRN in Q2 2013 and has held it in 39 quarters since. The position peaked at $22M in Q2 2022. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Verition Fund Management held 22,500 shares of BioMarin Pharmaceuticals worth $1.29M as of Q2 2026.
  • BioMarin Pharmaceuticals was a new Verition Fund Management position in Q2 2026.
  • BioMarin Pharmaceuticals made up 0.01% of Verition Fund Management's portfolio in Q2 2026, its #1330 holding.
  • Verition Fund Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 39 quarters since.
  • Verition Fund Management's BioMarin Pharmaceuticals position peaked at $22M in Q2 2022.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.